SGLT2 Amputation Lawsuits: Diabetes Drug Injury
Catastrophic Injury Lawyer and Product Liability Attorney investigates SGLT2 amputation, Fournier’s Gangrene and diabetes drug injury cases for plaintiffs nationwide
A recent study of nearly 35,000 patients with type 2 diabetes found sodium-glucose cotransporter 2 (SGLT2) inhibitors may double patient risk of lower limb amputation and diabetic ketoacidosis compared to alternative drugs.
The study, published in The BMJ, said SGLT2 inhibitors, which include medications like Invokana, Invokamet, Farxiga, Xigduo, Jardiance and Glyxambi, may pose significant amputation risks.
Researchers noted the following: “Case reports to the U.S. FDA Adverse Event Reporting System have indicated that SGLT2 inhibitors could cause diabetic ketoacidosis, acute kidney injury and serious urinary tract infection.
The researchers studied adverse outcomes including limb amputation, Fouriner’s gangrene, bone fracture, ketoacidosis, acute kidney injury, urinary tract infection and venous thromboembolism associated with SGLT2 inhibitors and GLP1 receptor agonists.
Joe Lyon is a highly-rated product liability lawyer representing plaintiffs nationwide in a wide variety of drug injury claims and SGLT2 amputation lawsuits against negligent pharmaceutical companies.
SGLT2 Injury Studies
In a prior study released, the New England Journal of Medicine published a report that concluded SGLT2 inhibitors may be linked with almost twice the risk of diabetic ketoacidosis as DPP4 inhibitors.
Other studies have warned of elevated risks of lower limb amputations, and the U.S. Food and Drug Administration (FDA) has advised physicians to discontinue the medication for patients with unusual pain, sores or lower extremity infection. Popular SLGT2 inhibitors on the market include:
- Xigduo XR
SGLT2 Inhibitor Side Effects & Complications
The risk of amputation may double during SGLT2 drug use in some patients. The FDA also warns of other serious side effects, including the following:
- Fournier’s Gangrene
- Acute pancreatitis
- Renal Failure
- Kidney Failure
- Heart Attacks
- Low blood pressure
- Serious urinary tract infections
- Bone fractures
Legal Action: SGLT2 Amputation Lawsuits
As early as 2015, the U.S. Food and Drug Administration (FDA) added warnings to labels of SGLT2 inhibitors regarding the risk of blood and kidney infection. In 2017 an FDA warning issued with Invokana warned of prescribing the drug to patients predisposed to amputations and other health complications.
If you or a loved one has suffered an injury after taking an SGLT-2 inhibitor drug, and have questions about the legal remedies available to improve quality of life and medical care, contact The Lyon Firm at (800) 513-2403. You will speak directly with Mr. Lyon, and he will help you answer critical questions about SGLT2 amputation lawsuits.